Loading...
Market
Which prophylactic strategy will be found most effective in J&J's ongoing studies by March 31, 2025?
2
Resolution / Starting Odds
Dexamethasone • 25%
Alternative corticosteroid • 25%
Combination therapy • 25%
None of the above • 25%
Johnson & Johnson official press release or peer-reviewed publication
Story
J&J: Dexamethasone Reduces Infusion Reactions in Lung Cancer Patients by 22.5%
Sep 10, 2024, 09:19 PM
Johnson & Johnson ($JNJ) has announced that dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous Rybrevant (amivantamab-vmjw). The prophylaxis regimen with 8 mg dexamethasone taken for two days prior to the first infusion met the primary endpoint of incidence of infusion-related reactions at C1D1. Ongoing studies are evaluating additional prophylactic strategies to further reduce these reactions. The pre-medication regimen showed an infusion-related reaction rate of 22.5% with intravenous Rybrevant.
View original story
Similar markets
Pfizer (KP.2) • 25%
Moderna (KP.2) • 25%
Novavax (JN.1) • 25%
All equally effective • 25%
Yes • 50%
No • 50%
Lenacapavir • 25%
Cabotegravir • 25%
Both equally • 25%
Neither dominates • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
Yes • 50%
No • 50%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
High efficacy • 25%
Moderate efficacy • 25%
Low efficacy • 25%
No significant efficacy • 25%
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
GSK • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%